singulair paediatric 5 mg chewable tablets
imed healthcare ltd. - montelukast - chewable tablet - 5 milligram(s) - leukotriene receptor antagonists; montelukast
singulair paediatric 4 mg chewable tablets
imed healthcare ltd. - montelukast - chewable tablet - 4 milligram(s) - leukotriene receptor antagonists; montelukast
singulair paediatric 5 mg chewable tablets
imbat limited - montelukast sodium - chewable tablet - 5 milligram(s) - leukotriene receptor antagonists; montelukast
singulair 4 mg tablets, chewable
msd (pty) limited, south africa - montelukast - tablets, chewable - 4 mg
singulair tablets chewable
merck sharp & dohme b.v. - montelukast (montelukast sodium) - tablets chewable - 4mg
singulair tablets chewable
merck sharp & dohme b.v. - montelukast (montelukast sodium) - tablets chewable - 5mg
singulair tablets chewable
merck sharp & dohme b.v. - montelukast (montelukast sodium) - tablets chewable - 4mg
singulair tablets chewable
merck sharp & dohme b.v. - montelukast (montelukast sodium) - tablets chewable - 5mg
singulair montelukast 4 mg (as sodium) tablet blister pack
organon pharma pty ltd - montelukast sodium, quantity: 4.16 mg (equivalent: montelukast, qty 4 mg) - tablet, chewable - excipient ingredients: aspartame; mannitol; iron oxide red; hyprolose; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; flavour - prophylaxis and treatment of chronic asthma in adults and children two years of age and over. symptomatic treatment of seasonal allergic rhinitis
singulair
merck sharp & dohme (new zealand) limited - montelukast sodium 4.16mg equivalent to 4 mg montelukast free acid - chewable tablet - 4 mg - active: montelukast sodium 4.16mg equivalent to 4 mg montelukast free acid excipient: aspartame cherry flavour 181612 croscarmellose sodium hyprolose iron oxide red magnesium stearate mannitol microcrystalline cellulose purified water - indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and nighttime symptoms and the prevention of exercise-induced bronchospasm.